• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

体外循环后鱼精蛋白-肝素相互作用激活补体的证据。

Evidence for complement activation by protamine-heparin interaction after cardiopulmonary bypass.

作者信息

Cavarocchi N C, Schaff H V, Orszulak T A, Homburger H A, Schnell W A, Pluth J R

出版信息

Surgery. 1985 Sep;98(3):525-31.

PMID:3875906
Abstract

Complement activation by the alternate pathway has been implicated in the pathophysiology of cardiopulmonary bypass (CPB), and laboratory studies suggest that the complement cascade may be activated by the protamine-heparin complex. To determine if the administration of protamine to patients receiving heparin activates complement, we studied 100 patients undergoing CPB by assaying levels of C3a and C4a (classic pathway) at regular intervals before and after protamine administration. In group I (90 patients), protamine was given at the usual interval (median 5 minutes) after CPB. In group II (10 patients), protamine was withheld until skin closure (median 45 minutes) after CPB. Results demonstrated that C4a was not activated during CPB in either group. After CPB, the C4a level in group I was 459 ng/dl and increased to 1047 ng/dl 10 minutes after protamine administration (p less than 0.001). In group II, the C4a level was 484 ng/dl at the end of CPB and 354 ng/dl 15 minutes later, which corresponds to the value immediately after protamine administration in group I. The delayed administration of protamine in group II caused a significant increase in C4a at the time of skin closure (1090 ng/dl; p less than 0.001). Corresponding results from C3a analysis before and after protamine administration confirmed the activation of complement cascade. Our study provides the first clinical evidence that the protamine-heparin complex activates complement via the classic (C4a) pathway. The hemodynamic effects of protamine after CPB may be related to complement activation.

摘要

旁路途径的补体激活与体外循环(CPB)的病理生理学有关,实验室研究表明补体级联反应可能由鱼精蛋白 - 肝素复合物激活。为了确定给接受肝素治疗的患者注射鱼精蛋白是否会激活补体,我们通过在注射鱼精蛋白前后定期检测C3a和C4a(经典途径)水平,对100例接受CPB的患者进行了研究。在第一组(90例患者)中,CPB后按常规间隔(中位数5分钟)给予鱼精蛋白。在第二组(10例患者)中,CPB后直到皮肤缝合(中位数45分钟)才给予鱼精蛋白。结果表明,两组在CPB期间C4a均未被激活。CPB后,第一组的C4a水平为459 ng/dl,注射鱼精蛋白10分钟后升至1047 ng/dl(p<0.001)。在第二组中,CPB结束时C4a水平为484 ng/dl,15分钟后为354 ng/dl,这与第一组注射鱼精蛋白后立即的值相当。第二组延迟给予鱼精蛋白导致皮肤缝合时C4a显著升高(1090 ng/dl;p<0.001)。鱼精蛋白注射前后C3a分析的相应结果证实了补体级联反应的激活。我们的研究提供了首个临床证据,即鱼精蛋白 - 肝素复合物通过经典(C4a)途径激活补体。CPB后鱼精蛋白的血流动力学效应可能与补体激活有关。

相似文献

1
Evidence for complement activation by protamine-heparin interaction after cardiopulmonary bypass.体外循环后鱼精蛋白-肝素相互作用激活补体的证据。
Surgery. 1985 Sep;98(3):525-31.
2
[Effect of complement 4 genetic polymorphism on complement activation during cardiopulmonary bypass in open heart surgery among children].
Zhonghua Yi Xue Za Zhi. 2001 Aug 10;81(15):918-20.
3
Heparin-protamine complexes and C-reactive protein induce activation of the classical complement pathway: studies in patients undergoing cardiac surgery and in vitro.肝素-鱼精蛋白复合物和C反应蛋白诱导经典补体途径的激活:对心脏手术患者及体外研究
Thromb Haemost. 2000 Aug;84(2):237-43.
4
Complement activation by heparin-protamine complexes during cardiopulmonary bypass: effect of C4A null allele.体外循环期间肝素-鱼精蛋白复合物激活补体:C4A无效等位基因的影响。
J Thorac Cardiovasc Surg. 1997 Sep;114(3):482-8. doi: 10.1016/S0022-5223(97)70197-1.
5
Effect of methylprednisolone on complement activation during heparin neutralization.甲基强的松龙对肝素中和过程中补体激活的影响。
J Cardiovasc Pharmacol. 1997 Jan;29(1):23-7. doi: 10.1097/00005344-199701000-00004.
6
Effects of protamine administration after cardiopulmonary bypass on complement, blood elements, and the hemodynamic state.
Ann Thorac Surg. 1986 Feb;41(2):193-9. doi: 10.1016/s0003-4975(10)62668-9.
7
Changes in platelet, granulocyte, and complement activation during cardiopulmonary bypass using heparin-coated equipment.使用肝素涂层设备进行体外循环期间血小板、粒细胞和补体激活的变化。
Artif Organs. 1996 Jul;20(7):767-76. doi: 10.1111/j.1525-1594.1996.tb04538.x.
8
Efficacy of a heparin removal device in comparison with protamine after hypothermic cardiopulmonary bypass.低温体外循环后肝素清除装置与鱼精蛋白相比的疗效
ASAIO J. 1997 Sep-Oct;43(5):M825-30.
9
Relationship between granulocyte elastase and C3a under protamine dosing in on-pump cardiac surgery.
Eur J Cardiothorac Surg. 2005 Sep;28(3):431-4. doi: 10.1016/j.ejcts.2005.05.020.
10
A new poly-2-methoxyethylacrylate-coated cardiopulmonary bypass circuit possesses superior platelet preservation and inflammatory suppression efficacy.一种新型的聚-2-甲氧基乙基丙烯酸酯涂层体外循环回路具有卓越的血小板保存和炎症抑制功效。
Ann Thorac Surg. 2004 May;77(5):1678-83. doi: 10.1016/j.athoracsur.2003.10.060.

引用本文的文献

1
The Impact of COVID-19 on Graft Vasculopathy and Postoperative Thromboembolism in CABG Patients: A Prospective Controlled Study.新冠病毒病对冠状动脉旁路移植术患者移植血管病变及术后血栓栓塞的影响:一项前瞻性对照研究
Cardiovasc Toxicol. 2025 Jun 10. doi: 10.1007/s12012-025-10017-3.
2
Strategies to attenuate maladaptive inflammatory response associated with cardiopulmonary bypass.减轻与体外循环相关的适应性炎症反应的策略。
Front Surg. 2024 Jul 3;11:1224068. doi: 10.3389/fsurg.2024.1224068. eCollection 2024.
3
Targeting the contact system in a rabbit model of extracorporeal membrane oxygenation.
针对兔体外膜肺氧合模型中的接触系统。
Blood Adv. 2023 Apr 25;7(8):1404-1417. doi: 10.1182/bloodadvances.2022007586.
4
Monocyte Metabolism and Function in Patients Undergoing Cardiac Surgery.心脏手术患者的单核细胞代谢与功能
Front Cardiovasc Med. 2022 Jul 13;9:853967. doi: 10.3389/fcvm.2022.853967. eCollection 2022.
5
Polymeric Nanocapsules for Vaccine Delivery: Influence of the Polymeric Shell on the Interaction With the Immune System.聚合物纳米胶囊用于疫苗传递:聚合物壳层对与免疫系统相互作用的影响。
Front Immunol. 2018 Apr 19;9:791. doi: 10.3389/fimmu.2018.00791. eCollection 2018.
6
Lung inflammatory response syndrome after cardiac-operations and treatment of lornoxicam.心脏手术后的肺部炎症反应综合征及氯诺昔康的治疗
J Thorac Dis. 2014 Mar;6 Suppl 1(Suppl 1):S78-98. doi: 10.3978/j.issn.2072-1439.2013.12.07.
7
Compstatin: a complement inhibitor on its way to clinical application.补体抑制剂compstatin:迈向临床应用之路
Adv Exp Med Biol. 2008;632:273-92. doi: 10.1007/978-0-387-78952-1_20.
8
Complement activation during cardiac and thoracic vascular operations.心脏和胸段血管手术期间的补体激活。
Tex Heart Inst J. 1987 Dec;14(4):369-72; discussion 372-3.
9
Low molecular weight protamine as nontoxic heparin/low molecular weight heparin antidote (III): preliminary in vivo evaluation of efficacy and toxicity using a canine model.低分子量鱼精蛋白作为无毒肝素/低分子量肝素解毒剂(III):使用犬模型进行疗效和毒性的初步体内评估。
AAPS PharmSci. 2001;3(3):E19. doi: 10.1208/ps030319.
10
Low molecular weight protamine (LMWP) as nontoxic heparin/low molecular weight heparin antidote (II): in vitro evaluation of efficacy and toxicity.低分子量鱼精蛋白(LMWP)作为无毒肝素/低分子量肝素解毒剂(II):疗效与毒性的体外评估
AAPS PharmSci. 2001;3(3):E18. doi: 10.1208/ps030318.